Department of Cardiothoracic Surgery, Lihuili Hospital affiliated to Ningbo University, Ningbo, Zhejiang 315041, China; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Department of Cardiothoracic Surgery, Lihuili Hospital affiliated to Ningbo University, Ningbo, Zhejiang 315041, China.
Stem Cell Res. 2021 Mar;51:102168. doi: 10.1016/j.scr.2021.102168. Epub 2021 Jan 12.
COVID-19 caused by a novel coronavirus named SARS-CoV-2, can elites severe acute respiratory syndrome, severe lung injury, cardiac injury, and even death and became a worldwide pandemic. SARS-CoV-2 infection may result in cardiac injury via several mechanisms, including the expression of angiotensin-converting enzyme 2 (ACE2) receptor and leading to a cytokine storm, can elicit an exaggerated host immune response. This response contributes to multi-organ dysfunction. As an emerging infectious disease, there are limited data on the effects of this infection on patients with underlying cardiovascular comorbidities. In this review, we summarize the early-stage clinical experiences with COVID-19, with particular focus on patients with cardiovascular diseases and cardiopulmonary injuries, and explores potential available evidence regarding the association between COVID-19, and cardiovascular complications.
由新型冠状病毒 SARS-CoV-2 引起的 COVID-19,可引起严重急性呼吸系统综合征、严重肺部损伤、心脏损伤,甚至死亡,并成为全球性大流行。SARS-CoV-2 感染可能通过多种机制导致心脏损伤,包括表达血管紧张素转换酶 2(ACE2)受体并导致细胞因子风暴,从而引发过度的宿主免疫反应。这种反应导致多器官功能障碍。作为一种新兴传染病,关于这种感染对伴有心血管合并症的患者的影响的数据有限。在这篇综述中,我们总结了 COVID-19 的早期临床经验,特别关注患有心血管疾病和心肺损伤的患者,并探讨了 COVID-19 与心血管并发症之间关联的潜在可用证据。